
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 16, 2008

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other Jurisdiction of
Incorporation)

0-26224

(Commission File Number)

51-0317849

(IRS Employer Identification No.)

**311 Enterprise Drive
Plainsboro, NJ**

(Address of Principal Executive Offices)

08536

(Zip Code)

Registrant's telephone number, including area code: **(609) 275-0500**

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 8.01 OTHER EVENTS

On May 16, 2008, Integra LifeSciences Holdings Corporation issued a press release announcing that it has scheduled a conference call for 9:00 AM EDT on Monday, May 19, 2008, to discuss its financial results for the fourth quarter and year ended December 31, 2007 and to update forward-looking financial guidance.

Access to the live call is available by dialing 913-312-0863 or through a webcast via a link provided on the Investor Relations homepage of Integra's website at www.Integra-LS.com. Access to a replay is available through May 26, 2008 by dialing 719-457-0820 (PIN 4115546) or through the webcast.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

99.1 Press release, dated May 16, 2008, issued by Integra LifeSciences Holdings Corporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: May 16, 2008

By: /s/ Stuart M. Essig
Stuart M. Essig
Title: President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press Release, dated May 16, 2008, issued by Integra LifeSciences Holdings Corporation.

News Release

Contact:

Integra LifeSciences Holdings Corporation

John B. Henneman III
Executive Vice President, Finance and Administration
Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com

Karen Mroz-Bremner
Senior Manager, Corporate Development
and Investor Relations
(609) 936-6929
karen.mroz-bremner@Integra-LS.com

Integra LifeSciences to Host 2007 Financial Results Conference Call on May 19

Plainsboro, New Jersey, May 16, 2008— Integra LifeSciences Holdings Corporation (NASDAQ:IART) has scheduled a conference call for 9:00 AM EDT on Monday, May 19, 2008 to discuss financial results for the fourth quarter and full year ended December 31, 2007 and to update forward-looking financial guidance. Financial results for the fourth quarter and full year 2007 will be announced via a news release prior to the conference call.

The conference call will be hosted by Stuart Essig, President and Chief Executive Officer of Integra, and will be open to all listeners. Additional forward-looking information may be discussed in a question and answer session following the call.

Access to the live call is available by dialing 913-312-0863 or through a webcast via a link provided on the Investor Relations homepage of Integra's website at www.Integra-LS.com. Access to a replay is available through May 26, 2008 by dialing 719-457-0820 (PIN 4115546) or through the webcast.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products are used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

IART-G

Source: Integra LifeSciences Holdings Corporation